Unlocking the Potential of Value-Based Healthcare in Mesothelioma Cancer Care

ByHolly Zink
Unlocking the Potential of Value-Based Healthcare in Mesothelioma Cancer Care

In the world of healthcare, there’s something called Value-Based Healthcare (VBHC). It’s all about making healthcare better by focusing on the results it delivers. When it comes to diseases like cancer, doctors want to get the best results for patients. A group of European healthcare centers came together in the VOICE community to see if they could make this happen.

Understanding Value-Based Healthcare

Value-Based Healthcare is all about understanding what works best in healthcare. It looks at the outcomes (results) that patients get from treatments and connects them to the costs. This way, doctors can see which treatments are worth it. The goal is to get the best results for the money spent by patients.

In the world of cancer, the focus is often on helping patients live longer. But it’s not just about how long you live; it’s also about your quality of life and the cost of treatment. That’s where Value-Based Healthcare comes in.

The First Step: Getting Data

To start using Value-Based Healthcare in cancer care, doctors need lots of information. The VOICE community collected data on patients’ reported outcomes, clinical outcomes, care process outcomes, and economic outcomes. This data helps researchers understand how patients feel. It looks at how their treatment is going. And it takes into account how much treatment costs.

The Challenge: Benchmarking in Cancer

Benchmarking is like comparing different healthcare centers to see who does things best. In this study, they looked at six healthcare centers in three countries to see how they were doing in cancer treatment.

Here’s what that found. Patients had different health outcomes. Some centers did better in care process, while others didn’t. And the costs of treatment varied. The interesting part is that by comparing these centers, doctors can figure out what’s working well. If one center is doing a great job in a certain area, others can learn from them.

Moving Forward with Value-Based Healthcare

This study is just the beginning. Value-Based Healthcare has a lot of potential to make healthcare better. The next step is to keep collecting data, sharing best practices, and improving the way doctors care for mesothelioma patients.

Cancer is a serious disease, but with the power of Value-Based Healthcare, doctors can make a real difference in how doctors treat it. The journey to better healthcare is an exciting one, and we’re on the right path.

Source:

García-Lorenzo, Borja, Ania Gorostiza, Itxaso Alayo, Susana Castelo Zas, Patricia Cobos Baena, Inés Gallego Camiña, Begoña Izaguirre Narbaiza, et al. “European Value-Based Healthcare Benchmarking: Moving from Theory to Practice.” European Journal of Public Health, October 24, 2023, ckad181. https://doi.org/10.1093/eurpub/ckad181.

Similar Posts

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    ByAlex Strauss

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • |

    Study Lists Factors That Impact Mesothelioma Prognosis

    ByAlex Strauss

    Predicting survival in mesothelioma patients does not have to be complicated. A new Parisian study suggests that simple-to-measure factors such as patient age and the histological subtype of the mesothelioma can be highly accurate prognostic indicators. The study followed 170 patients diagnosed with malignant pleural mesothelioma between 2000 and 2010 at Saint Antoine Hospital in Paris. Patients in the study were all treated non-surgically. For each patient, a list of parameters was recorded including age, gender, tobacco use, asbestos exposure, type and duration of symptoms, BMI, C-reactive protein levels and white blood cell and platelet counts.  Inflammation of the pleura (pachypleuritis) was also noted, along with the type of diagnostic surgical procedure, histological subtype, the way in which pleurodesis was performed (for…

  • |

    Predicting Mesothelioma Outcomes with Blood Tests

    ByAlex Strauss

    Two separate teams of Japanese researchers are delving into the possibilities of blood serum indicators that could help predict outcomes in patients with malignant pleural mesothelioma. Mesothelioma is a rare but aggressive cancer caused by exposure to asbestos. Pleural mesothelioma, a cancer that starts on the lining around the lungs, is the most common form of the disease. It occurs most often in people who have inadvertently inhaled asbestos dust. Mesothelioma is highly resistant to conventional treatments. It is also difficult to predict which patients are likely to do well with standard therapies and which are not, which is referred to as prognosis. But researchers worldwide are continually searching for new ways to diagnose and predict the prognosis of patients with…

  • |

    Drop in Lung Volume Predicts Poor Mesothelioma Outcome

    ByAlex Strauss

    Decreases in lung volume may be an indicator of treatment response for patients with mesothelioma. Researchers in the U.S. and Australia reached that conclusion after studying the cases of 61 patients with malignant pleural mesothelioma and 216 CT scans taken of them during the course of their standard chemotherapy treatment. Lung volume is a measurement of the amount of air the lung processes (inhales, exhales and holds on to) during the course of a normal breath. People with malignant pleural mesothelioma, a cancer that starts on the lining around the lungs, typically experience a drop in lung volume as the pleural tumor grows and constricts or even invades one of their lungs. The new study measured changes in each mesothelioma patient’s…

  • |

    New Prognostic Tools Could Improve Mesothelioma Treatment

    ByAlex Strauss

    A pair of cancer researchers from Rome say treatment for malignant pleural mesothelioma could be improved if more clinicians considered the newest prognostic tools in their treatment planning. Pleural mesothelioma is a malignancy of the membranes that encase the lungs. It is caused by exposure to the mineral asbestos and is highly resistant to conventional cancer therapies. Many mesothelioma patients do not survive longer than 12 months from the onset of their symptoms. But Tommaso Mineo, MD, and Vincenzo Ambrogi, PhD, of the Department of Experimental Medicine and Surgery at Policlinico Tor Vergata University say newly discovered biomarkers and other tumor factors could lead to more tailored treatment and, potentially, better outcomes. “Therapy is currently guided by gross tumor characteristics and patient…

  • |

    For Some Patients Chemo Cuts Mesothelioma Survival

    ByAlex Strauss

    Asbestos disease researchers in Australia say chemotherapy at the end of life may be doing some mesothelioma patients more harm than good. The team from the Asbestos Diseases Research Institute in Rhodes, Australia analyzed the cases of 147 malignant pleural mesothelioma patients who had received compensation from the government’s Dust Diseases Board. The focus of the study was to determine the association between a variety of factors such as age, gender, geographic location, disease stage, histological subtype, length of first-line chemotherapy, and the use of chemotherapy in the last month of their lives. Among the mesothelioma patients studied, most (77%) received more than one treatment modality while 56% received only one. Chemotherapy, which continues to be the most popular first-line treatment…